



Patient Information	Specimen Information	Client Information
<b>POTTER, DAVID</b>  <b>DOB: 04/08/1969    AGE: 49</b> Gender: M    Fasting: N Phone: 818.415.9596 Patient ID: 36167507	Specimen: EN949794Y Requisition: 0001503 Lab Ref #: 36167507  Collected: 06/22/2018 / 08:03 PDT Received: 06/23/2018 / 03:42 PDT Reported: 06/23/2018 / 13:46 PDT	Client #: 97505886    MAIL000 RAMOS, CARLOS HEALTH TESTS DIRECT-OHS-MEDIVO Attn: JEAN H. POOLE 3303 HARBOR BLVD STE G2 COSTA MESA, CA 92626-1522

COMMENTS:    FASTING:NO

Test Name	In Range	Out Of Range	Reference Range	Lab
THYROID PANEL WITH TSH				
THYROID PANEL				EN
T3 UPTAKE	35		22-35 %	
T4 (THYROXINE), TOTAL	6.6		4.5-12.0 mcg/dL	
FREE T4 INDEX (T7)	2.3		1.4-3.8	
TSH	4.26		0.40-4.50 mIU/L	EN
LIPID PANEL				
<b>CHOLESTEROL, TOTAL</b>		<b>215 H</b>	<200 mg/dL	EN
HDL CHOLESTEROL	73		>40 mg/dL	EN
TRIGLYCERIDES	53		<150 mg/dL	EN
<b>LDL-CHOLESTEROL</b>		<b>128 H</b>	mg/dL (calc)	EN
Reference range: <100				
Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors.				
LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164)				
CHOL/HDL-C RATIO	2.9		<5.0 (calc)	EN
<b>NON HDL CHOLESTEROL</b>		<b>142 H</b>	<130 mg/dL (calc)	EN
For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.				
COMPREHENSIVE METABOLIC				EN
PANEL				
GLUCOSE	89		65-139 mg/dL	
Non-fasting reference interval				
UREA NITROGEN (BUN)	22		7-25 mg/dL	
CREATININE	0.89		0.60-1.35 mg/dL	
eGFR NON-AFR. AMERICAN	100		> OR = 60 mL/min/1.73m2	
eGFR AFRICAN AMERICAN	116		> OR = 60 mL/min/1.73m2	
BUN/CREATININE RATIO	NOT APPLICABLE		6-22 (calc)	
SODIUM	141		135-146 mmol/L	
POTASSIUM	4.9		3.5-5.3 mmol/L	
CHLORIDE	103		98-110 mmol/L	
<b>CARBON DIOXIDE</b>		<b>33 H</b>	20-31 mmol/L	
CALCIUM	10.0		8.6-10.3 mg/dL	
PROTEIN, TOTAL	7.6		6.1-8.1 g/dL	
ALBUMIN	4.7		3.6-5.1 g/dL	
GLOBULIN	2.9		1.9-3.7 g/dL (calc)	
ALBUMIN/GLOBULIN RATIO	1.6		1.0-2.5 (calc)	
BILIRUBIN, TOTAL	0.5		0.2-1.2 mg/dL	
ALKALINE PHOSPHATASE	67		40-115 U/L	
AST	16		10-40 U/L	



Patient Information	Specimen Information	Client Information
<b>POTTER, DAVID</b>  <b>DOB: 04/08/1969    AGE: 49</b> Gender: M    Fasting: N Patient ID: 36167507	Specimen: EN949794Y Collected: 06/22/2018 / 08:03 PDT Received: 06/23/2018 / 03:42 PDT Reported: 06/23/2018 / 13:46 PDT	Client #: 97505886 RAMOS, CARLOS

Test Name	In Range	Out Of Range	Reference Range	Lab
ALT	22		9-46 U/L	
PHOSPHATE (AS PHOSPHORUS)	3.3		2.5-4.5 mg/dL	EN
URIC ACID	5.6		4.0-8.0 mg/dL	EN
Therapeutic target for gout patients: <6.0 mg/dL				
LD	160		100-220 U/L	EN
GGT	15		3-95 U/L	EN
CBC (INCLUDES DIFF/PLT)				EN
WHITE BLOOD CELL COUNT	5.6		3.8-10.8 Thousand/uL	
RED BLOOD CELL COUNT	5.48		4.20-5.80 Million/uL	
HEMOGLOBIN	15.7		13.2-17.1 g/dL	
HEMATOCRIT	46.7		38.5-50.0 %	
MCV	85.2		80.0-100.0 fL	
MCH	28.6		27.0-33.0 pg	
MCHC	33.6		32.0-36.0 g/dL	
RDW	11.9		11.0-15.0 %	
PLATELET COUNT	215		140-400 Thousand/uL	
MPV	10.1		7.5-12.5 fL	
ABSOLUTE NEUTROPHILS	3142		1500-7800 cells/uL	
ABSOLUTE LYMPHOCYTES	1747		850-3900 cells/uL	
ABSOLUTE MONOCYTES	560		200-950 cells/uL	
ABSOLUTE EOSINOPHILS	123		15-500 cells/uL	
ABSOLUTE BASOPHILS	28		0-200 cells/uL	
ABSOLUTE NUCLEATED RBC	0		0 cells/uL	
NEUTROPHILS	56.1		%	
LYMPHOCYTES	31.2		%	
MONOCYTES	10.0		%	
EOSINOPHILS	2.2		%	
BASOPHILS	0.5		%	
IRON, TOTAL	116		50-180 mcg/dL	EN



Patient Information	Specimen Information	Client Information
<b>POTTER, DAVID</b>  <b>DOB: 04/08/1969    AGE: 49</b> Gender: M              Fasting: N Patient ID: 36167507	Specimen: EN949794Y Collected: 06/22/2018 / 08:03 PDT Received: 06/23/2018 / 03:42 PDT Reported: 06/23/2018 / 13:46 PDT	Client #: 97505886 RAMOS, CARLOS

**Immunology**

Test Name	Result	Reference Range	Lab
ANA SCREEN, IFA, W/REFL TITER AND PATTERN			EN
ANA SCREEN, IFA	NEGATIVE	NEGATIVE	
ANA IFA is a first line screen for detecting the presence of up to approximately 150 autoantibodies in various autoimmune diseases. A negative ANA IFA result suggests ANA-associated autoimmune diseases are not present at this time.  Visit Physician FAQs for interpretation of all antibodies in the Cascade, prevalence, and association with diseases at <a href="http://education.QuestDiagnostics.com/faq/FAQ177">http://education.QuestDiagnostics.com/faq/FAQ177</a>			
Physician Comments:			

**PERFORMING SITE:**

EN    QUEST DIAGNOSTICS-WEST HILLS, 8401 FALLBROOK AVENUE, WEST HILLS, CA 91304-3226 Laboratory Director: TAB TOOCHINDA,MD, CLIA: 05D0642827